Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 14
Rare complications of neurofibromatosis 1 diagnosed incidentally in two children
Authors Lazea C, Asavoaie C, Al-Khzouz C, Popa L
Received 15 May 2018
Accepted for publication 13 June 2018
Published 31 August 2018 Volume 2018:14 Pages 1547—1552
DOI https://doi.org/10.2147/TCRM.S173237
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Cecilia Lazea,1 Carmen Asavoaie,2 Camelia Al-Khzouz,3 Lenuta Popa1
1Department of Pediatrics I, Emergency Clinic Hospital for Children, “Iuliu Hatieganu” University of Medicine and Pharmacy, 2Department of Imaging and Radiology, Emergency Clinic Hospital for Children, 3Medical Genetics Department, Emergency Clinic Hospital for Children, University of Medicine and Pharmacy, Cluj-Napoca, Romania
Abstract: Neurofibromatosis 1 (NF1) is an autosomal-dominant disorder with various clinical expressivity and complications. Arterial hypertension may be present in patients with NF1 and is secondary to vasculopathy or pheochromocytoma. We herein describe two children (17 and 4 years old) diagnosed late with NF1 after severe arterial hypertension had been discovered due to pheochromocytoma and middle aortic syndrome. Routine measurement of arterial pressure is mandatory in children with NF1, in order to diagnose the complications of this disease.
Keywords: neurofibromatosis, pheochromocytoma, middle aortic syndrome, arterial hypertension, children
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.